Emerging Pharma: Strategies for Optimizing Manufacturing and Supply
with Networking Reception
Date/Time: Wednesday, March 21, 2018 - 2:00 PM to 4:00 PM
Room: InterContinental Barclay - Grand Ballroom
New program to DCAT Week! Emerging Pharma delivers practical insights for emerging pharmaceutical companies and their partners in development and manufacturing about how they can move their pipelines forward.
Who Should Attend?
Emerging Pharmaceutical Companies
This program has been developed to assist emerging pharmaceutical companies in making the all-important decisions for developing and implementing a successful development and launch strategy. For these companies, delivering on key milestones requires an effective supply strategy to avoid delays in development and cost overtures and for meeting investors’ expectations. With so much at stake, this program will deliver first-hand insight from industry experts on the key success factors and pitfalls to avoid. (This program and reception is open to, and complimentary for, qualifying non-member emerging pharmaceutical companies. Please register below and further information/confirmation will be sent to you via email.)
Note: Emerging pharmaceutical companies refer to innovator pharmaceutical companies that operate largely as clinical-stage pharmaceutical/biopharmaceutical companies with no or very limited commercial drugs.
DCAT Member Companies
For member companies of the DCAT organization, this program provides valuable learnings for optimizing partnerships with emerging pharma companies, an important customer base for suppliers and a source of product innovation for larger pharmaceutical companies. (This program and reception is open to DCAT members, and they are asked to support it with a registration fee of $69.00 per person.)
Member companies are also encouraged to urge those qualifying non-member emerging pharma companies which they know of or might be currently working with to apply for the complimentary registration.
The program will feature:
- Pricing, Payers, and Pipelines: The Impact on Drug Development and Commercialization
Learn how trends in drug pricing and the payer/reimbursement environment are impacting product development and commercialization, including how manufacturing and product-design choices can impact downstream pricing and coverage.
Speaker: Roshawn A. Blunt, Managing Director, 1789 Consultants, Inc.
- CDMO/CMO Selection and Management
Get a view from "inside the trenches" of lessons learned for selecting the right development and launch partner in terms of scale, capabilities, and phase of development. Gain best practices in supplier relationship management when working with contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs).
Speaker: James Kanter, Senior Director, API Engineering, Ardelyx
- Manufacturing and Due Diligence
The clinical potential of a drug candidate drives partnerships and acquisitions with larger pharmaceutical companies, but how does manufacturing factor into the due-diligence process for such deals? Gain practical insight on manufacturing assessments made in due diligence and how to meet partners' preferences in manufacturing and supply arrangements, including for risk mitigation, and how to facilitate contract assumption in external development and manufacturing.
Speaker: To Be Announced
Following the presentations, all registered attendees are invited to a Post-Program Networking Reception.
- Time: 4:00 PM - 5:30 PM
- Room: InterContinental Barclay, Grand Ballroom
- Member Company Price: $69.00
- Emerging Pharma Company Price: Complimentary
- Non-Member Price: Sorry, no non-member guests who do not fit the outlined criteria
- Doors open at 1:30 PM for coffee & networking prior to the program.
|Registration for DCAT Member Companies||Registration for Emerging Pharma Companies|